17R-resolvin D1

17R-resolvin D1 is a specialized pro-resolving lipid mediator (SPM) and a 17R epimer of resolvin D1, biosynthesized endogenously from docosahexaenoic acid (DHA) via sequential oxygenation. It is commonly called aspirin-triggered resolvin D1, reflecting increased formation when DHA metabolism is "triggered" by aspirin[1][3][5][7]. 17R-resolvin D1 exhibits potent anti-inflammatory and pro-resolving properties by suppressing inflammatory cytokines (TNF-α, IL-1β, IL-6), reducing leukocyte infiltration, inhibiting NLRP3 inflammasome activation, and blocking NF-κB signaling[3][4][6][7]. It has shown therapeutic potential in animal models of pressure overload-induced cardiac hypertrophy and fibrosis, sickle cell disease, peritonitis, arthritis, sepsis, and NSAID-induced intestinal damage[1][3][4][6].

Other names

17R-resolvin D1aspirin-triggered resolvin D1AT-RvD1AT-RvD-1AT-RvD 1